Phase 1/2Not yet recruiting

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)

A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)

Sponsor
Xynomic Pharmaceuticals, Inc. (Industry)
Enrollment
221 planned
Conditions
Cancer; BRAF V600 Mutation; Melanoma; Colorectal Cancer; Thyroid Cancer; Nonsmall Cell Lung Cancer
Interventions
XP-102; Trametinib
Ages
adults, older adults
Registry
NCT05275374

Full record on ClinicalTrials.gov

From the registry

This is a first-in-human multi-center study which will be conducted in advanced malignant solid tumors patients. The solid tumor type is limited to melanoma, colorectal, non-small-cell lung, and thyroid cancer with positive BRAF V600 mutation. This study is divided into three stages: Phase Ia: a dose-escalation phase of XP-102; Phase Ib: a dose-escalation and sample size expansion phase of XP-102 plus trametinib; Phase IIa: an expansion phase of XP-102 plus trametinib.

Primary outcomes

  • Characterize the safety of XP-102.
  • Evaluate the pharmacokinetics of XP-102.
  • Establish maximum tolerated dose of XP-102.

History

  1. Study completion expected

  2. Primary completion expected

  3. Started

  4. Last registry update

  5. Registered